^
Association details:
| Biomarker: | B2M-HLA-E fusion |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | CB-011 (BCMA-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
524 - CB-011, a BCMA-Specific Allogeneic CAR-T Cell Therapy, Engineered with Next-Generation CRISPR Technology to Express an HLA-E Fusion Transgene to Prevent Immune Cell-Mediated Rejection, for r/r Multiple Myeloma
Published date:
12/16/2022
Excerpt:
CAR-T cells expressing the B2M–HLA-E fusion exhibited a survival advantage vs cells lacking the fusion protein in the presence of NK cells in vitro, suggesting that CB-011 cells may resist rapid rejection by a patient’s NK cells and potentially persist longer. Single dose CB-011 CAR-T cell treatment led to long-term survival in immunodeficient mice bearing established orthotopically-engrafted MM tumor cells... These studies support the safety and efficacy profiles of CB-011 for an upcoming first-in-human phase 1 clinical trial evaluating these allogeneic BCMA-specific CAR-T cells in patients with r/r MM.
Source:
Title:
LB009 / 9 - A BCMA-specific allogeneic CAR-T cell therapy (CB-011) genome-engineered to express an HLA-E fusion transgene to prevent immune cell rejection
Published date:
03/09/2022
Excerpt:
To demonstrate that the B2M-HLA-E fusion protein expression protects CB-011 from NK-mediated cell killing, we developed an in vitro competition assay in which CB-011 cells are co-incubated with NK cells. We observed that CAR-T cells expressing the B2M-HLA-E fusion have a survival advantage over cells that do not express the fusion in the presence of NK cells in vitro, indicating that they could resist killing by a recipient’s NK cells and potentially circulate longer....The BCMA-specific CAR leads to long-term survival in mice bearing established orthotopically-engrafted MM tumor cells.
